CPT code 80326 represents a laboratory toxicology assay that detects or measures five or more amphetamines in a patient specimen. This code is used for multi-analyte amphetamine testing and is relevant across clinical settings where confirmation of amphetamine exposure or monitoring is required, including emergency departments, outpatient clinics, pain management programs, substance use treatment, and forensic or occupational testing contexts. Nationally, standardized coding for multi-amphetamine panels aids in consistent reporting, billing, and surveillance of stimulant use.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and coding considerations for laboratory toxicology services using CPT code 80326.

Readers will find a concise overview of the clinical context for multi-amphetamine testing, the typical service setting, and the role of CPT code 80326 in claims. The report summarizes benchmarks and common billing modifiers where available, highlights implications for clinical workflows and lab operations, and flags areas where policy or coverage variability may affect reimbursement and utilization. Data not available in the input is explicitly noted where applicable.